Table 4 Selected ongoing clinical trials investigating immunotherapy in combination with agents targeting resistance mechanisms
Clinicaltrial.gov identifier | Trial design | Rationale/phase of trial/current status | Study group |
|---|---|---|---|
NCT03095781 | Pembrolizumab and XL888 (HSP90 inhibitor) in patients with advance gastrointestinal cancers | Enhancing immune response by upregulating interferon response/Phase 1b/recruiting | Previously treated advanced gastrointestinal cancers |
NCT02675946 | CGX1321 in subjects with advanced solid tumours and CGX1321 with pembrolizumab in subjects with advanced gastrointestinal tumours (Keynote 596) | Combination of checkpoint inhibitor with Wnt inhibitor to enhance the efficacy/Phase 1b/recruiting | Previously treated advanced gastrointestinal cancers |
NCT02947165 | Phase I/Ib study of NIS793 in combination with PDR001 in patients with advanced malignancies | Combination of TGF-β inhibitor with anti-PD-1 inhibitor/Phase 1b/recruiting | Advanced solid tumours |
NCT03638297 | PD-1 antibody combined with COX inhibitor in MSI-H/MMR-D or high tumour mutation burden colorectal cancer | Combining COX-2 inhibitor with an anti-PD1 inhibitor to enhance the efficacy/Phase 2/recruiting | Previously treated MSI-H colorectal cancer |
NCT03607890 | A study of nivolumab and relatlimab in advanced MMR-D cancers resistant to prior PD-(L)1 inhibitor | Combining anti-LAG3 antibody with an anti-PD1 inhibitor to enhance the efficacy/Phase 2/recruiting | MSI-H colorectal cancer with previous PD-(L)1 exposure |
NCT03608046 | A study of subcutaneous nivolumab monotherapy with or without recombinant human hyaluronidase PH20 (rHuPH20) | Combining stroma modifying agent with anti-PD1 to enhance the efficacy/Phase 1/recruiting | Previously treated advanced gastrointestinal cancers |
NCT03126110 | Phase 1/2 study exploring the safety, tolerability, and efficacy of INCAGN01876 combined with immune therapies in advanced or metastatic malignancies | Combining anti-human glucocorticoid-induced tumour necrosis factor receptor with combination of a checkpoint inhibitor to obtain more sustained response | Advanced solid tumours |
